Download this complimentary Expert Insights eBook today!
Producing therapeutic antibodies at clinical scale demands cell lines that are both highly productive and genetically stable — yet identifying them requires extensive, costly screening. This Expert Insights eBook highlights how Droplet Digital™ PCR (ddPCR™) Technology is transforming that process: from CRISPR-based host engineering through clone selection to long-term stability monitoring of production pools.
For Research Use Only. Not for use in diagnostic procedures.
Inside this Expert Insights eBook, you’ll learn:
- Why ddPCR technology outperforms conventional qPCR for copy number determination — eliminating standard curves and resolving differences that qPCR cannot detect
- How ddPCR systems verified that each engineered cell contained exactly the right number of gene copies, a critical quality check in a new Bristol Myers Squibb cell line platform that consistently produced high antibody yields and shortened the path to clinical trials by 2.5 to 3 months
- How Genentech used ddPCR solutions to confirm that working with cell pools instead of individual clones remained genetically stable over months of growth, delivering clinical-grade material around 3 months ahead of schedule
Click “LOOK INSIDE” to download the PDF now.
More Information
ddPCR™ technology has emerged as a unifying analytical platform across the cell line development workflow. By partitioning reactions across tens of thousands of nanoliter droplets, it enables absolute, standard-curve-free quantification that far exceeds the precision of conventional qPCR. Whether confirming CRISPR-based genome edits at fractional abundances below 0.5%, verifying transgene copy number during clone selection, or monitoring genetic stability of production pools over many generations, ddPCR solutions reduce variability and accelerates decision-making at every stage. Combined with targeted integration strategies that replace unpredictable random transgene insertion with site-specific genomic placement, these technologies are shortening timelines, cutting costs, and improving confidence in the quality of therapeutic antibodies reaching patients.
For Research Use Only. Not for use in diagnostic procedures.
Sponsored by
